Homoeopathic Sector Raises Concerns Over DRAP Raids in Pakistan

The Homoeopathic Pharmaceutical and Chemist Association (HPCA) Pakistan has strongly criticized the Drug Regulatory Authority of Pakistan (DRAP) and Punjab Health Ministry over alleged raids and regulatory delays affecting the homoeopathic sector.

The association claims that manufacturers are facing harassment through inspections and sealing of units while thousands of medicine approval cases remain pending with DRAP.

Industry representatives argue that despite heavy investment and compliance with registration procedures, the sector is still struggling due to slow regulatory processing and enforcement actions.

Key Issues Overview

Major Concerns Raised

Regulatory Approval Delays

HPCA states that thousands of homoeopathic medicine applications remain pending for years, slowing industry growth and product availability.

Enforcement Actions and Raids

Manufacturing units and stores are reportedly facing raids, fines, and closures, creating uncertainty for registered businesses.

Demand for Fair Treatment

The association has urged authorities to stop harassment and engage in formal discussions to resolve regulatory issues.

Industry Context

HPCA compared Pakistan’s situation with India’s AYUSH system, where alternative medicine is formally integrated into healthcare, education, and research systems.

Conclusion

The situation highlights ongoing tension between regulatory enforcement and industry development in Pakistan’s homoeopathic sector. Stakeholders are demanding faster approvals, transparent policies, and improved coordination to support sustainable industry growth.